(PharmaNewsWire.Com, January 03, 2017 ) According to Publisher, the Global Autoimmune Disease Therapeutics Market is accounted for $51.2 billion in 2015 and is expected to reach $82.13 billion by 2022 growing at a CAGR of 6.9% during the forecast period. Rising healthcare expenditure in the region is one of the key factors fueling the market growth. On the other hand, insufficient funding in emerging countries and high cost involved in the treatment of the disease are hindering the market. Biologics drug acts as initial line of treatment due to therapeutic capabilities in controlling and treatment of different autoimmune complications.
North America is the largest market for autoimmune disease therapeutics due to increasing incidence of different forms of autoimmune disorders, and government initiatives in the region. Europe is expected to be the second largest market due to rising healthcare infrastructure and penetration of new technologies.
Some of the key players in the market include Johnson & Johnson Inc, Bayer Schering Pharma AG, Elan Corporation Plc, Abbott Laboratories, Genentech Inc, GlaxoSmithKline Plc, Bristol-Myers Squibb, Chugai Pharmaceutical Co. Ltd., Merck & Co. Inc, Amgen Inc, Eli Lilly and Company, F. Hoffmann-La Roche AG, Biogen Idec Inc, Teva Pharmaceuticals, Industries Limited, UCB S.A., Sanofi-Aventis SA, Novartis AG and Shire Plc.
Distribution Channel: - Drug Stores - Hospitals - Independent Pharmacies - Clinics
Drug Class Covered: - Anti-Inflammatory Drugs - Biologics - Immunosuppressant's - Nonsteroidal anti-inflammatory drugs - Corticosteroids
Regions Covered: - North America - US - Canada - Mexico - Europe - Germany - France - Italy - UK - Spain - Rest of Europe - Asia Pacific - Japan - China - India - Australia - New Zealand - Rest of Asia Pacific - Rest of the World - Middle East - Brazil - Argentina - South Africa - Egypt
What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements
Company Profiling 9.1 Johnson & Johnson Inc 9.2 Bayer Schering Pharma AG 9.3 Elan Corporation Plc 9.4 Abbott Laboratories 9.5 Genentech Inc 9.6 GlaxoSmithKline Plc 9.7 Bristol-Myers Squibb 9.8 Chugai Pharmaceutical Co. Ltd. 9.9 Merck & Co. Inc 9.10 Amgen Inc 9.11 Eli Lilly and Company 9.12 F. Hoffmann-La Roche AG 9.13 Biogen Idec Inc 9.14 Teva Pharmaceuticals Industries Limited 9.15 UCB S.A. 9.16 Sanofi-Aventis SA 9.17 Novartis AG 9.18 Shire Plc
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: